Literature DB >> 3121354

Influence of experimental rhinitis on the gonadotropin response to intranasal administration of buserelin.

C Larsen1, M Niebuhr Jørgensen, B Tommerup, N Mygind, E E Dagrosa, H G Grigoleit, V Malerczyk.   

Abstract

The influence of experimental rhinitis on the absorption of buserelin, measured as the serum luteinizing hormone (LH) response, has been investigated. A single dose of 200 micrograms buserelin was given to 24 healthy male volunteers after induction of experimental rhinitis with histamine and after use of a saline spray (placebo control). Except on one occasion, when the pump-spray apparently was incorrectly operated, serum LH concentration rose after buserelin. There was no difference in the LH response between histamine-induced rhinitis and saline controls. It was concluded that intranasal application of buserelin represents a reliable mode of application and that modification of the administration route or a change in the dosage schedule during naturally-occurring nasal inflammations, such as the common cold and allergic rhinitis, is unnecessary in patients undergoing chronic treatment with intranasal buserelin, e.g. for prostatic cancer, endometriosis, precocious puberty, and contraception.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3121354     DOI: 10.1007/bf00544560

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  15 in total

1.  Long-term endocrine profiles of prostatic carcinoma patients under pernasal as well as intramuscular Gn-RH analogue treatment.

Authors:  U K Wenderoth; G H Jacobi
Journal:  Prog Clin Biol Res       Date:  1985

2.  Inhibition of ovulation in women by chronic treatment with a stimulatory LRH analogue--a new approach to birth control?

Authors:  S J Nillius; C Bergquist; L Wide
Journal:  Contraception       Date:  1978-06       Impact factor: 3.375

3.  Rhinomanometry. I. Simple equipment.

Authors:  P Broms; A Ivarsson; B Jonson
Journal:  Acta Otolaryngol       Date:  1982 May-Jun       Impact factor: 1.494

4.  Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (Buserelin) as a new therapeutic approach for endometriosis.

Authors:  A Lemay; R Maheux; N Faure; C Jean; A T Fazekas
Journal:  Fertil Steril       Date:  1984-06       Impact factor: 7.329

5.  Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists.

Authors:  G Tolis; D Ackman; A Stellos; A Mehta; F Labrie; A T Fazekas; A M Comaru-Schally; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

6.  Sustained suppression of testosterone production by the luteinising-hormone releasing-hormone agonist buserelin in patients with advanced prostate carcinoma. A new therapeutic approach?

Authors:  V Borgmann; W Hardt; M Schmidt-Gollwitzer; H Adenauer; R Nagel
Journal:  Lancet       Date:  1982-05-15       Impact factor: 79.321

7.  Preliminary results on the clinical efficacy and safety of androgen inhibition by an LHRH agonist alone or combined with an antiandrogen in the treatment of prostatic carcinoma.

Authors:  N Faure; A Lemay; B Laroche; G Robert; R Plante; C Jean; M Thabet; R Roy; A T Fazekas
Journal:  Prostate       Date:  1983       Impact factor: 4.104

8.  Intranasal treatment with luteinising hormone releasing hormone agonist in women with endometriosis.

Authors:  R W Shaw; H M Fraser; H Boyle
Journal:  Br Med J (Clin Res Ed)       Date:  1983-12-03

9.  Significance of H1 and H2 receptors in the human nose: rationale for topical use of combined antihistamine preparations.

Authors:  C Secher; J Kirkegaard; P Borum; A Maansson; P Osterhammel; N Mygind
Journal:  J Allergy Clin Immunol       Date:  1982-09       Impact factor: 10.793

10.  Potential new treatment of endometriosis: reversible inhibition of pituitary-ovarian function by chronic intranasal administration of a luteinizing hormone-releasing hormone (LH-RH) agonist.

Authors:  A Lemay; G Quesnel
Journal:  Fertil Steril       Date:  1982-09       Impact factor: 7.329

View more
  6 in total

Review 1.  Buserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical profile.

Authors:  R N Brogden; M M Buckley; A Ward
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

Review 2.  Intranasal drug delivery. Potential advantages and limitations from a clinical pharmacokinetic perspective.

Authors:  A E Pontiroli; A Calderara; G Pozza
Journal:  Clin Pharmacokinet       Date:  1989-11       Impact factor: 6.447

Review 3.  Intranasal insulin. Clinical pharmacokinetics.

Authors:  L Illum; S S Davis
Journal:  Clin Pharmacokinet       Date:  1992-07       Impact factor: 6.447

4.  Mucoadhesive polymers in peroral peptide drug delivery. VI. Carbomer and chitosan improve the intestinal absorption of the peptide drug buserelin in vivo.

Authors:  H L Luessen; B J de Leeuw; M W Langemeÿer; A B de Boer; J C Verhoef; H E Junginger
Journal:  Pharm Res       Date:  1996-11       Impact factor: 4.200

5.  The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis.

Authors:  W C Shyu; K A Pittman; D S Robinson; R H Barbhaiya
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

6.  Bioavailability and pharmacokinetics of intranasal hydromorphone in patients experiencing vasomotor rhinitis.

Authors:  George A Davis; Anita C Rudy; Sanford M Archer; Daniel P Wermeling; Patrick J McNamara
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.